Simulations Plus

Showcases platform momentum, strategic priorities, and long-term value creation outlook

Investor Day on January 21, 2026, to present new product vision and AI solutions

Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem

Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET

Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework

Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10

Fourth quarter and fiscal year 2025 results to be reported December 1, 2025

Simulations Plus to Participate in Upcoming Investor Conferences

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing

Investment to accelerate innovations in biopharma development through Corporate Development Initiative

Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment

Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations

Modeling and simulation will be a key component for shift to non-animal methodologies

Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training

Total revenue grew 23% year-over-year driven by strong growth in both software and services

Simulations Plus will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor.

Industry partners to provide funding and data to support ACAT™ model improvements

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare

Total revenue up 31% year-over-year primarily driven by strong software growth